Articles tagged with Cell Therapies
Researchers have developed a new type of cell therapy called HIT cells that can detect and eliminate cancer cells in mice with pancreatic, kidney and ovarian cancers. The treatment shows promise for nearly 20 other types of cancers, including glioblastoma and pancreaticadenocarcinoma.
Researchers in Lund have presented a new model for cooperation that will shorten lead times and reduce costs. The Cell and Gene Therapy Navigator tool helps identify imbalances and future bottlenecks in projects.
Aviv Regev, a pioneering computational biologist, will deliver a keynote address on tissue stem cells at the ISSCR 2026 Annual Meeting. Her work has transformed our understanding of cell and tissue function in health and disease.
Dr. George Coukos, a leading authority on tumor immunology and cellular immunotherapy, joins Weill Cornell Medicine to lead the Ludwig Laboratory for Cell Therapy.
The ISSCR has released a comprehensive roadmap for developing pluripotent stem cell-derived therapies, outlining critical scientific, manufacturing, and regulatory guidance. The Best Practices document provides a risk-based, end-to-end development strategy to support informed decision-making across seven essential areas.
Researchers at Sanford Burnham Prebys found that transplanted stem cells develop neurons with unique codes to navigate and form connections in the brain. These codes guide the growth of axons and explain why most neurons of a particular subtype send axons to specific brain regions.
Researchers at University of British Columbia have successfully grown specialized immune cells called helper T cells from stem cells in a controlled laboratory setting. This breakthrough could lead to more accessible and effective off-the-shelf treatments for various conditions, including cancer, autoimmune disorders, and infectious di...
A novel approach to chronic pain management uses induced pluripotent stem cell-derived peripheral pain-sensing neurons to treat osteoarthritis joint pain. The therapy, SN101, sequesters inflammatory pain factors without transmitting pain signals, preserving joint tissues and relieving chronic pain.
Researchers successfully used microglia replacement to halt a fatal neurological disease in human patients, marking a significant advancement from initial mouse model success. The approach has evolved into an efficient and clinical meaningful strategy, with potential applications across neurological diseases.
Scientists at Southwest Research Institute (SwRI) have successfully replicated induced Pluripotent Stem Cells (iPSCs) using a new application of their cell-expansion bioreactor. The bioreactor's unique geometry allows for the growth of large quantities of iPSCs, which can differentiate into any other cell type in the body.
The International Society for Stem Cell Research invites you to celebrate 20 years of induced pluripotent stem cell (iPSC) discovery and chart its future. The symposium features keynote speakers, featured sessions, and presentations on cutting-edge research.
Researchers at UCLA have developed CAR-NKT cell therapy, which can attack tumors from multiple fronts while dismantling their protective shields. The therapy uses engineered immune cells that can be mass-produced from donated blood stem cells and stored ready-to-use, offering a potentially life-changing treatment option.
The ISSCR 2026 Annual Meeting will bring together academic and industry leaders to explore advances in stem cell science and regenerative medicine. Scientists can submit abstracts by February 25, 2026, for oral presentations and Travel and Merit Awards.
The International Society for Stem Cell Research (ISSCR) has released a comprehensive guide to accelerate the translation of human pluripotent stem cell-derived therapies into clinical trials and commercial use. The guidance outlines key principles and decision points for developing safe, effective, and regulatory-compliant products.
Researchers develop antibody-γδ T cell conjugates to target PD-L1-positive cancers, inducing pyroptosis and remodeling tumor microenvironment. This dual action promotes direct killing of cancer cells and sustained anti-tumor immunity.
Oral mucositis increases infection risks in stem cell transplant patients by nearly four times, according to new research. A superior AI tool has been introduced to accurately predict these risks, enabling targeted oral care before transplants and reducing complications.
The DKMS John Hansen Research Grant is supporting innovative research projects in blood cancer therapy, aiming to improve treatment outcomes. The grant, worth almost €1 million, will support young scientists with a focus on transplant immunology and novel diagnostic and therapeutic strategies.
A team of researchers at Memorial Sloan Kettering Cancer Center has made a groundbreaking discovery about why genetically engineered immune cells sometimes fail to fully destroy tumors. They found that FAS ligand, produced by the immune cells themselves, causes self-destruction and reduces therapy's effectiveness.
The Weill Cancer Hub West will harness expertise from two world-class institutions to accelerate new discoveries and develop innovative treatments. The initiative aims to drive early detection, diagnoses, and effective treatments through data science and human cell research.
Researchers identified a protective RNA molecule that regulates autophagic flux and protects against cellular injury, inflammation, and fibrosis in kidney cells. Boosting this tRNA-Asp-GTC-3'tDR increases kidney protection with less scarring, inflammation, and injury.
Researchers found that inhibiting the GLUD1 enzyme improves muscle strength and coordination in DMD mouse models, offering a potential therapeutic pathway for treating the disease. The study suggests a promising approach to restore muscle function beyond symptom relief.
Researchers identified key factors behind a successful immunotherapy response in a young patient with rhabdoid tumour. The study highlights the potential of sequencing technologies to track immune cell profiles and develops personalized cell therapies.
Scientists found that mesenchymal stromal cells (MSC) therapy improved immune recovery in cats with FIP, a disease similar to Long COVID. The study showed reduced systemic inflammation and increased regulatory T cells, suggesting potential benefits for human patients.
A new treatment method using microglia replacement has shown promising results in halting the progression of genetic neurological disease ALSP in both mice and human individuals. The treatment, developed at Fudan University, successfully replaced mutated microglia with healthy ones, improving neurological function and extending life ex...
Researchers at the University of Cambridge have made a groundbreaking discovery on how neural stem cell grafts can restore myelin in MS lesions in mice. The study provides critical evidence supporting the safety and efficacy of human induced neural stem cell transplantation as a potential new treatment for progressive multiple sclerosis.
A new gene therapy delivery device called NANOSPRESSO could revolutionize how hospitals treat rare diseases by allowing them to create personalized nanomedicines in-house. This democratized approach to precision medicine could boost access to low-cost bespoke gene and RNA therapies, especially in low-resource settings.
CIK cell therapy improved overall and progression-free survival for patients with colorectal cancer, regardless of disease stage. Serum CEA levels can predict treatment response, paving the way for a simple blood test.
Physicians from Ruhr-University Bochum used CAR T-cell therapy to treat two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disease causing paralysis and loss of sensation. The treatment showed rapid and long-lasting effects, with significant improvements in symptoms and functional abilities.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Researchers developed a new method to study mechanical proteins, revealing that disrupting protein titin causes muscle disease. The technique allows for targeted analysis of protein mechanics, paving the way for new therapeutic strategies.
Researchers at MSK uncovered a key signaling molecule involved in the body's immune response against leptomeningeal metastasis. A new grading system to assess thrombocytopenia risk after CAR T cell therapy was also developed. Additionally, a statistical method called UnitedMet estimates metabolic characteristics from challenging clinic...
Researchers discovered 500 cryptic peptides found only in pancreatic tumors, which could be targeted by vaccines or engineered T cells to attack the cancer. The peptides were identified using immunopeptidomics and shown to slow down tumor growth in mice.
Researchers identified CLU protein as a potential strategy to protect against Alzheimer's disease by increasing clusterin protein. Increased CLU protects the brain from amyloid plaques and loss of synapses, while identifying individuals most likely to respond based on their genetics.
Scientists have discovered a novel immune signaling pathway in bacteria that turns viral infection machinery against the virus, potentially informing future biotech tools and phage therapy. This discovery reveals an ancient defense strategy that could help fight superbugs.
This study explored the immune dynamics across different phases of HBV infection, identifying key factors influencing T cell function and liver priming. The research team uncovered distinct types of intrahepatic T lymphocytes and dual roles of DC-SIGN+ macrophages in modulating immune responses.
AIC100 demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, including anaplastic thyroid cancer (ATC) and relapsed/refractory poorly differentiated thyroid cancer (PTDC). The therapy showed significant tumor shrinkage and disease control in 56% of patients.
A Phase I clinical trial reveals that HSP-CAR30 CAR-T cell therapy promotes the expansion of memory T cells, leading to long-lasting responses and improved clinical outcomes in treated patients. The treatment exhibits a favorable safety profile, with no dose-limiting toxicities detected.
A new clinical study has treated its first patient with a novel therapy aimed at difficult-to-treat melanoma skin cancer tumors. The treatment uses modified immune-system T cells to target PRAME, a peptide found in many melanoma tumor cells.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
Researchers at MIT developed a control circuit that can precisely regulate gene expression levels, improving the efficacy and safety of gene therapy treatments. The 'COMMAND' circuit uses microRNA to suppress gene expression, allowing for tighter control over treatment outcomes.
The treatment demonstrated early signals of efficacy, with 65.7% of patients experiencing lasting stable disease, and was generally well-tolerated, with most adverse events being mild and manageable.
A clinical trial found that LUT014, a topical BRAF inhibitor, significantly reduced the severity of acne-like skin rashes caused by targeted therapy for colorectal cancer. Patients who received LUT014 had improved quality of life and were able to continue receiving their cancer treatment with reduced side effects.
Researchers develop nanoparticle-based therapy combining hydroxyl-enriched fullerenol and mTOR inhibitors to disrupt cancer cells' organelle communication system. The approach triggers a synergistic "nanomaterial + metabolic modulation" anticancer strategy, establishing a new hope for treating aggressive cancers.
A novel topical BRAF inhibitor gel called LUT014 has been shown to significantly reduce the severity of an acne-like rash in patients undergoing anti-EGFR therapies for colorectal cancer. The treatment's safety and effectiveness have been confirmed, offering a potential solution to managing this common side effect.
Researchers at Northwestern University propose a new approach to therapeutic development using structural precision in nanomedicine. By fine-tuning the interaction between nanomedicines and the human body, scientists can design interventions that are more effective, targeted, and beneficial for patients.
A new study reports on five patients with Canavan disease who have a novel variant identified through targeted long-read sequencing, revealing an SVA_E retrotransposable element that disrupts gene function. The findings enhance genetic diagnostics and enable improved guidance for families.
Researchers at MD Anderson Cancer Center present promising results from clinical trials in three minisymposia abstracts. The studies explore personalized vaccine combination therapy for colorectal cancer, radiotherapy to avoid toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancrea...
A phase 1 trial involving 40 patients showed significant responses to the new cell therapy IMA203, with half of non-responders achieving lasting response. The therapy targets PRAME peptide produced by many tumors and was well-tolerated.
A new machine learning model accurately predicts the fitness of AAV capsids based on their amino acid sequence, enabling more efficient and cost-effective gene therapies. The model's robustness and generalizability have been demonstrated through tests on independent datasets, offering a promising tool for capsid engineering.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center are presenting new findings on combination therapies for liver and pancreatic cancers, including a new organoid model for personalized head and neck cancer treatment. Additionally, they are discussing the potential of liquid biopsies for cancer detection and monitoring.
Researchers have uncovered the molecular mechanism of ATG-9 in regulating lysosome integrity by modulating phospholipid distribution. This study suggests that reduced ATG-9 scramblase activity facilitates lysosome biogenesis and repair, highlighting ATG-9 as a promising therapeutic target for diseases related to lysosomal dysfunction.
Researchers discovered that endoperoxides derived from ergosterol and 7-dehydrocholesterol induce the death of melanoma cells. This finding paves the way for expanding the use of photodynamic therapy in fighting skin cancer.
A study reveals that Galectin-1 protein, located in fibroblast nuclei, promotes tumor growth and resistance to treatment. The protein regulates gene expression at a specific level, activating KRAS, a key driver of uncontrolled growth and tumor aggressiveness.
Researchers discovered that aging causes inflammation, oxidative stress, and gene disruption in the retinal pigment epithelium, a vital layer of cells in the eye. This study provides a clearer understanding of why aging leads to eye disease and introduces a reliable laboratory model for testing new therapies.
Researchers have developed an innovative optical genome mapping technique that can identify structural variants and copy number variations across the entire genome in a single test. The method has been shown to reduce material requirements and improve prognostic stratification for patients with multiple myeloma.
A new method using UV light and machine learning can detect microbial contamination in cell cultures, providing a quicker yes/no assessment within 30 minutes. This technology aims to reduce the time spent on sterility tests, making it crucial for life-saving treatments.
Researchers used CRISPR interference to examine every gene in the human genome and discovered a new set of genes contributing to Parkinson's disease risk. The study identified the Commander complex, which regulates lysosomal function and is implicated in PD risk, offering opportunities for new treatments.
Researchers at Moffitt Cancer Center have found that a natural protein called CD40L can improve the speed and success of TIL manufacturing, potentially benefiting more patients. The study showed that CD40L-enhanced TILs grew successfully in 67% of samples when used, compared to 33% without it.
Researchers found that GSK3β becomes increasingly active in melanoma cells during treatment, helping them survive and adapt despite BRAF inhibitors. Treating resistant cancer cells with a GSK3β inhibitor significantly reduced their growth, suggesting blocking this protein could restore sensitivity to treatment.
A phase 1 clinical trial will evaluate the safety and efficacy of CLBR001 + SWI019 in patients with myositis, systemic sclerosis, lupus and rheumatoid arthritis. The therapy has the potential to reduce side effects and patient burden associated with traditional CAR-T approaches.